Actively Recruiting
Randomized Phase 2 Trial of AP31969 Tablets Versus Placebo for Managing Atrial Fibrillation Rhythm
Led by Acesion Pharma · Updated on 2026-09-30
200
Participants Needed
46
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effectiveness and safety of different doses of the drug AP31969 in reducing the burden of Atrial Fibrillation AF. The trial is a randomized Phase 2 study comparing several doses of AP31969 against a placebo in adults diagnosed with paroxysmal or persistent AF. Participants are carefully selected based on their AF history and burden, and the study monitors heart rhythm using implanted devices. Participants are assigned randomly to one of five groups receiving oral tablets twice daily for 12 weeks AP31969 at doses of 100 mg, 200 mg, 350 mg, or 500 mg added later, or a placebo without active properties. The study consists of three main periods screening up to 4 weeks, treatment 12 weeks, and a follow-up period of 30 days, totaling about 20 weeks. During the study, participants receive an implantable loop recorder to continuously monitor heart rhythm. Throughout the trial, participants undergo several assessments including blood and urine tests, electrocardiograms, and continuous rhythm monitoring via the loop recorder. The main outcome measured is the AF burden from weeks 2 to 12, with additional measures including the number of AF episodes, quality of life changes, and ventricular tachycardia episodes. Safety and adherence are closely monitored, and the follow-up period helps assess sustained effects and participant well-being after treatment ends.
CONDITIONS
Brief Title
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
Research Team
B
Birgitte Vestbjerg
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here